BackIntelligent Medicine Acquisition Overview
Intelligent Medicine Acquisition Corp - Class A

Intelligent Medicine Acquisition Return on Equity

Intelligent Medicine Acquisition (IQMD) has a ROE of 2157193.89%, above the sector sector average of -4.47%.

Get informed when a big investor buys or sells

+ Follow

ROE

2157193.89%

Return on Equity

2157193.89%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Intelligent Medicine Acquisition (IQMD) FAQ

Intelligent Medicine Acquisition (IQMD) currently reports a ROE of 2157193.89%. That is above the sector sector average of -4.47%. Use the charts on this page to explore Intelligent Medicine Acquisition's ROE history and peer comparisons.

Intelligent Medicine Acquisition's ROE of 2157193.89% is higher than the its sector sector average of -4.47%. That is roughly 48277235.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Intelligent Medicine Acquisition's current 2157193.89% should be judged against industry norms (sector average: -4.47%) and against IQMD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 2157193.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.47%. From there, open related valuation or income-statement pages for Intelligent Medicine Acquisition, and consider following IQMD for alerts when major investors trade the stock.